Neutrophil-to-Lymphocyte-to-Platelet Ratio Predicts Acute Kidney Injury in Critically Ill Heart Failure Patients

Why It Matters

Early identification of patients at heightened AKI risk enables targeted interventions, potentially reducing mortality and resource use in a vulnerable heart‑failure population.

Key Takeaways

• NLPR combines neutrophil, lymphocyte, platelet counts into single metric
• Study of 3,942 ICU heart‑failure patients from MIMIC‑IV
• Highest NLPR quartile raised AKI risk by 30% (HR 1.30)
• Elevated NLPR linked to severe AKI, dialysis need, lower 30‑day survival
• NLPR is readily available at ICU admission for early stratification

Pulse Analysis

Acute kidney injury remains a leading cause of death among patients hospitalized for heart failure, driven by fluctuating perfusion, systemic inflammation, and neuro‑hormonal activation. Traditional risk scores rely on hemodynamic variables that are often unavailable or delayed, prompting clinicians to seek bedside biomarkers that capture the intertwined inflammatory and thrombotic pathways underlying cardiorenal syndrome. The neutrophil‑to‑lymphocyte‑to‑platelet ratio (NLPR) merges three routine blood counts into a single index, reflecting both immune activation and coagulopathy, two hallmarks of AKI pathogenesis.

In the recent MIMIC‑IV cohort study, researchers demonstrated a graded, independent association between NLPR and AKI incidence. Patients in the top NLPR quartile experienced a 30% increase in AKI risk compared with those in the lowest quartile, even after adjusting for age, comorbidities, and baseline renal function. Moreover, the analysis uncovered a non‑linear dose‑response curve, indicating that modest elevations already signal heightened vulnerability, while extreme values portend severe AKI stages, greater reliance on renal replacement therapy, and diminished 30‑day survival. These findings reinforce the concept that composite inflammatory‑thrombotic markers can outperform isolated laboratory values in prognosticating renal outcomes.

For intensive‑care practitioners, the practical appeal of NLPR lies in its immediacy and cost‑effectiveness; the required cell counts are part of standard admission panels, eliminating the need for specialized assays. Incorporating NLPR into electronic alerts could trigger early nephrology consultation, fluid‑management optimization, and avoidance of nephrotoxic agents. Nonetheless, prospective validation across diverse health‑system settings is essential before widespread adoption. Future research should explore whether NLPR‑guided interventions can actually lower AKI incidence or improve survival, potentially reshaping risk‑stratification protocols for the high‑risk heart‑failure cohort.